Mealey's (June 28, 2021, 2:53 PM EDT) -- PHILADELPHIA — Defendants in a securities class action lawsuit brought by investors of a generic drug company who allege that the company and certain of its current and former executive officers engaged in an illegal price-fixing scheme with competitors asked a federal judge in Pennsylvania on June 23 to grant summary judgment in their favor on lead plaintiffs’ remaining federal securities law claims because the lead plaintiffs have failed to provide sufficient evidence that would allow their claims to proceed....